I haven't thought about it because I have no desire to increase my exposure to NASH, and I also feel like VKTX is the *only* sensible investment in this space right now because the NASH product is derisked. And you have the support of a superior GLP-1/GIP potentially with an oral formulation, and the X-ALD program is a likely home run (well, in the context of the other programs it's more like a single, but it's a nice add on). All of these act as backstops. In contrast, most other NASH companies are single agent with all the attendant risk
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.